Haemonetics Corporation (HAE) Stock Analysis
Healthcare · Medical Devices · NYSE
Haemonetics Corporation (HAE) posted $1.33B in revenue for fiscal 2026 (down 2.0% year over year), at a 7.3% net margin, and has compounded revenue about 8.9%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Haemonetics Corporation
Haemonetics Corporation has grown revenue from $886.12M to $1.33B over the last 10 fiscal years, compounding about 8.9% a year. The most recent year was down 2%, so growth has cooled from its longer-run pace.
Net margin sits at 7.3%, down 5 points year over year on a 59% gross margin. It carries about $1.24B of total debt.
At today's valuation the market is pricing in roughly 2.6% annual free-cash-flow growth — versus the 29.4% it actually delivered over the last five years, so the price is arguably undemanding against what it has already proven.
Synthesised from Haemonetics Corporation's SEC filings — descriptive, not advice. Ask the analyst your own question →
Haemonetics Corporation revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $886.12M | $903.92M | $967.58M | $988.48M | $870.46M | $993.20M | $1.17B | $1.31B | $1.36B | $1.33B |
| Gross profit | $378.49M | $411.91M | $417.54M | $484.51M | $397.84M | $505.50M | $615.10M | $691.55M | $748.96M | $787.59M |
| Net income | $-26.27M | $45.57M | $55.02M | $76.53M | $79.47M | $43.38M | $115.40M | $117.56M | $167.68M | $97.31M |
| Net margin | -3.0% | 5.0% | 5.7% | 7.7% | 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% |
Source: Haemonetics Corporation SEC filings (10-K). 18 years of history available in the interactive view.
Haemonetics Corporation: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
What growth is priced into HAE stock?
At today's market cap of $3.58B, Haemonetics Corporation is priced for free-cash-flow growth of about 2.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $260.44M from the FY ending 2026-03-31). For comparison, free cash flow actually grew 29.4%/yr over the last five fiscal years and revenue 8.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Haemonetics Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HAE in your portfolio →
Haemonetics Corporation financial history by metric
Compare Haemonetics Corporation with peers
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics Corporation — frequently asked questions
What is Haemonetics Corporation's revenue?
Haemonetics Corporation (HAE) reported revenue of $1.33B for fiscal year 2026, down 2.0% from the prior year, according to its SEC filings.
Is Haemonetics Corporation profitable?
Yes. HAE earned net income of $97.31M in fiscal 2026, a net margin of 7.3%.
What is HAE's P/E ratio?
Haemonetics Corporation trades at a price-to-earnings ratio of about 38.4 based on the latest data in our nightly-refreshed cache.
How fast is Haemonetics Corporation growing?
HAE's revenue grew at roughly 8.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Haemonetics Corporation have?
As of fiscal year 2026, HAE carried roughly $1.24B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Haemonetics Corporation's gross margin?
HAE's gross margin was 59.0% in fiscal 2026 — gross profit of $787.59M on revenue of $1.33B.
What is Haemonetics Corporation's market cap?
Haemonetics Corporation (HAE) has a market capitalization of about $3.58B, based on the latest data in our nightly-refreshed cache.
When does Haemonetics Corporation's fiscal year end?
HAE's fiscal year ends in March. Its most recent annual filing covers the fiscal year ending 2026-03-31.
What growth is priced into HAE stock?
At today's market cap of $3.58B, Haemonetics Corporation is priced for free-cash-flow growth of about 2.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $260.44M from the FY ending 2026-03-31). For comparison, free cash flow actually grew 29.4%/yr over the last five fiscal years and revenue 8.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Haemonetics Corporation's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.